Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

CIGNA CORPORATION

(CI)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

CIGNA CORP : Regulation FD Disclosure (form 8-K)

05/28/2021 | 06:22am EDT

Item 7.01 Regulation FD Disclosure.

Cigna Corporation ("Cigna" or the "Company") officials expect to participate in meetings with investors and analysts over the next several weeks. During these meetings, Cigna officials expect to reaffirm projected full year 2021 consolidated adjusted revenues of at least $166 billion, projected full year 2021 consolidated adjusted income from operations of at least $7.0 billion, projected full year 2021 consolidated adjusted income from operations on a per share basis of at least $20.20 per share, and projected 2021 weighted average shares outstanding in the range of 346 million to 348 million. This outlook includes approximately $1.25 per share in net unfavorable impacts of COVID-19, as well as the impact of future share repurchases and anticipated 2021 dividends.

Cigna previously discussed its full year 2021 outlook in its press release and investor presentation dated May 7, 2021 and during the related investor conference call. The press release, presentation and the conference call transcript are available in the Investor Relations section of Cigna's website located at www.cigna.com. Forward-looking statements in these documents and the related call speak only as of the date they were made.

Adjusted revenues is defined as total revenues excluding special items and Cigna's share of certain realized investment results of its joint ventures reported in the International Markets segment using the equity method of accounting. Cigna excludes these items because management believes they are not indicative of past or future underlying performance of the business. Adjusted income (loss) from operations is defined as shareholders' net income (loss) excluding the following adjustments: net realized investment results, amortization of acquired intangible assets and special items. Cigna's share of certain realized investment results of its joint ventures reported in the International Markets segment using the equity method of accounting are also excluded. Adjusted income (loss) from operations is a measure of profitability used by Cigna's management because it presents the underlying results of operations of Cigna's businesses and permits analysis of trends in underlying revenue, expenses and shareholders' net income. These consolidated measures are not determined in accordance with accounting principles generally accepted in the United States of America ("GAAP") and should not be viewed as a substitute for the most directly comparable GAAP measure, total revenues and shareholders' net income (loss), respectively. Management is not able to provide a reconciliation to total revenues or shareholders' net income on a forward-looking basis because we are unable to predict certain components thereof including (i) future net realized investment results and (ii) future special items. These items are inherently uncertain and depend on various factors, many of which are beyond our control. As such, any associated estimate and its impact on total revenues and shareholders' net income could vary materially.

Cigna currently intends to pay regular quarterly dividends, with future declarations subject to approval by its Board of Directors and the Board's determination that the declaration of dividends remains in the best interests of Cigna and its shareholders. The decision of whether to pay future dividends and the amount of any such dividends will be based on the Company's financial position, results of operations, cash flows, capital requirements, the requirements of applicable law and any other factors the Board of Directors may deem relevant.

The timing and actual number of shares repurchased will depend on a variety of factors, including price, general business and market conditions, and alternate uses of capital. The share repurchase program may be effected through open market purchases in compliance with Rule 10b-18 under the Securities Exchange Act of 1934, as amended, including through Rule 10b5-1 trading plans, or privately negotiated transactions. The program may be suspended or discontinued at any time.

This information shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act whether made before or after the date of this report, except as shall be expressly set forth by specific reference in such a filing.

-2-






 CAUTIONARY STATEMENT FOR PURPOSES OF THE SAFE HARBOR PROVISIONS OF THE PRIVATE
                    SECURITIES LITIGATION REFORM ACT OF 1995

This Current Report on Form 8-K (the "Report"), and oral statements made with respect to information contained in this Report, may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are based on Cigna's current expectations and projections about future trends, events and uncertainties. These statements are not historical facts. Forward-looking statements may include, among others, statements concerning our projected adjusted income from operations for 2021 on a consolidated and per share basis, projected adjusted revenue for 2021, and projected weighted average shares outstanding included in Item 7.01 of this Report; as well as statements concerning future financial or operating performance, including our ability to deliver affordable, predictable and simple solutions for our customers and clients, including in light of the challenges presented by the COVID-19 pandemic; future growth, business strategy, strategic or operational initiatives; economic, regulatory or competitive environments, particularly with respect to the pace and extent of change in these areas; financing or capital deployment plans and amounts available for future deployment; our prospects for growth in the coming years; strategic transactions; and other statements regarding Cigna's future beliefs, expectations, plans, intentions, liquidity, cash flows, financial condition or performance. You may identify forward-looking statements by the use of words such as "believe," "expect," "plan," "intend," "anticipate," "estimate," "predict," "potential," "may," "should," "will" or other words or expressions of similar meaning, although not all forward-looking statements contain such terms.

Forward-looking statements are subject to risks and uncertainties, both known and unknown, that could cause actual results to differ materially from those expressed or implied in forward-looking statements. Such risks and uncertainties include, but are not limited to: our ability to achieve our strategic and operational initiatives; our ability to adapt to changes in an evolving and rapidly changing industry; the scale, scope and duration of the COVID-19 pandemic and its potential impact on our business, operating results, cash flows or financial condition, our ability to compete effectively, differentiate our products and services from those of our competitors and maintain or increase market share; price competition and other pressures that could compress our margins or result in premiums that are insufficient to cover the cost of services delivered to our customers; the potential for actual claims to exceed our estimates related to expected medical claims; our ability to develop and maintain satisfactory relationships with physicians, hospitals, other health service providers and with producers and consultants; our ability to maintain relationships with one or more key pharmaceutical manufacturers or if payments made or discounts provided decline; changes in the pharmacy provider marketplace or pharmacy networks; changes in drug pricing or industry pricing benchmarks; political, legal, operational, regulatory, economic and other risks that could affect our multinational operations; risks related to strategic transactions and realization of the expected benefits of such transactions, as well as integration difficulties or underperformance relative to expectations; dependence on success of relationships with third parties; risk of significant disruption within our operations or among key suppliers or third parties; our ability to invest in and properly maintain our information technology and other business systems; our ability to prevent or contain effects of a potential cyberattack or other privacy or data security incident; potential liability in connection with managing medical practices and operating pharmacies, onsite clinics and other types of medical facilities; the substantial level of government regulation over our business and the potential effects of new laws or regulations or changes in existing laws or regulations; uncertainties surrounding participation in government-sponsored programs such as Medicare; the outcome of litigation, regulatory audits, investigations; compliance with applicable privacy, security and data laws, regulations and standards; potential failure of our prevention, detection and control systems; unfavorable economic and market conditions, stock market or interest rate declines, risks related to a downgrade in financial strength ratings of our insurance subsidiaries; the impact of our significant indebtedness and the potential for further indebtedness in the future; unfavorable industry, economic or political conditions; credit risk related to our reinsurers; as well as more specific risks and uncertainties discussed in our most recent report on Form 10-K and subsequent reports on Forms 10-Q and 8-K available through the Investor Relations section of www.cigna.com. You should not place undue reliance on forward-looking statements, which speak only as of the date they are made, are not guarantees of future performance or results, and are subject to risks, uncertainties and assumptions that are difficult to predict or quantify. Cigna undertakes no obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise, except as may be required by law.

-3-

© Edgar Online, source Glimpses

All news about CIGNA CORPORATION
07:59aCIGNA : Announces Updates to its Board of Directors (Form 8-K)
PU
06:29aDAVID CORDANI : Cigna Names CEO Cordani Chairman
DJ
06:18aCIGNA CORP : Change in Directors or Principal Officers, Other Events, Financial ..
AQ
07/28Cigna Corporation Declares Quarterly Dividend, Payable on September 23, 2021
CI
07/22Cigna and Oscar Health, Inc. Launches Oscar Virtual Primary Care on Select Ci..
CI
07/15CIGNA : Bonnie Evelyn Named Cigna Market President for Georgia/Alabama
AQ
07/13Cigna Appoints Bonnie Evelyn as Market President for Its Health Care and Rela..
CI
06/25CIGNA CORPORATION(NYSE : CI) dropped from Russell 3000 Growth Index
CI
06/25CIGNA CORPORATION(NYSE : CI) dropped from Russell 3000E Growth Index
CI
06/25CIGNA CORPORATION(NYSE : CI) dropped from Russell Top 200 Growth Index
CI
More news
Financials (USD)
Sales 2021 167 B - -
Net income 2021 5 430 M - -
Net Debt 2021 24 363 M - -
P/E ratio 2021 14,4x
Yield 2021 2,19%
Capitalization 78 563 M 78 563 M -
EV / Sales 2021 0,62x
EV / Sales 2022 0,56x
Nbr of Employees 72 963
Free-Float 86,0%
Chart CIGNA CORPORATION
Duration : Period :
Cigna Corporation Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends CIGNA CORPORATION
Short TermMid-TermLong Term
TrendsBearishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 25
Last Close Price 228,95 $
Average target price 295,00 $
Spread / Average Target 28,8%
EPS Revisions
Managers and Directors
David Michael Cordani President, Chief Executive Officer & Director
Brian C. Evanko Chief Financial Officer & Executive Vice President
Isaiah Harris Independent Chairman
Steven B. Miller Chief Clinical Officer & Executive Vice President
Noelle K. Eder Global Chief Information Officer & Executive VP
Sector and Competitors
1st jan.Capi. (M$)
CIGNA CORPORATION9.98%78 563
UNITEDHEALTH GROUP17.51%388 881
ANTHEM, INC.18.33%93 706
HUMANA INC.7.44%55 353
CENTENE CORPORATION15.08%40 277
MOLINA HEALTHCARE, INC.21.86%14 904